Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/23768
OPTIMIZATION OF COMBINATION CHEMOTHERAPY BASED ON THE CALCULATION OF NETWORK ENTROPY FOR PROTEIN-PROTEIN INTERACTIONS IN BREAST CANCER CELL LINES
Affilliation
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Laboratório de Modelagem de Sistemas Biológicos. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Laboratório de Modelagem de Sistemas Biológicos. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil.
University of Alberta. Faculty of Medicine & Dentistry. Department of Oncology. Department of Physics. Edmonton, Alberta, Canada.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Laboratório de Modelagem de Sistemas Biológicos. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Ciência e Tecnologia de Inovação em Doenças Negligenciadas. Rio de Janeiro, RJ, Brasil.
University of Alberta. Faculty of Medicine & Dentistry. Department of Oncology. Department of Physics. Edmonton, Alberta, Canada.
Abstract
Background In this report, we show how entropy computation can be applied to the characterization of a protein-protein interaction networks to assist the selection of personalized chemotherapeutic strategy for cancer treatment.
Methods With seven malignant (BT-20, BT-474, MDA-MB-231, MDA-MB-468, MCF-7, T-47D, ZR-75-1) and one healthy (MCF10A) cell lines, we combined interactome and transcriptome data as well as Shanon entropy computation to classify drugs according to their inhibitory potential and to identify the top-5 protein targets best suited for personalized chemotherapy.
Results We have investigated breast cancer cell lines and found that the entropy of their protein interaction networks is negatively correlated with their sensitivity to target-specific drugs of high potency. This sensitivity is defined as half cell growth inhibition (GI50) with respect to drug administration. By contrast, we found no correlation for drugs that are either of low potency or with no specific molecular targets (cytotoxic). As a result, drugs can be divided into target specific and generally cytotoxic according to the GI50 they produce in malignant cell lines. By extrapolation, we predict that the inactivation of the top-5 up-regulated protein hubs by specific drugs will reduce the protein network entropy by ~2 %, on average, which is expected to substantially increase the benefit of a personalized chemo-therapeutic strategy for patient survival.
Conclusions We propose several novel drug combinations using only the approved drugs for the inactivation of the target identified in this study with the purpose of increasing patient survival and lowering the deleterious side effects of cancer chemotherapy.
Share